Pharmacokinetic and pharmacodynamic analyses and dose rationale for lefamulin, a novel pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia Preface

被引：0
|
作者：
Hurley, James C.
Ostrosky-Zeichner, Luis
Slavin, Monica
机构：
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2019年 / 74卷
关键词：
D O I：
10.1093/jac/dkz157
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：1 / 1
页数：1
相关论文
共 50 条
  • [1] Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia
    Watkins, Richard R.
    File, Thomas M., Jr.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (10) : 2757 - 2762
  • [2] Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia
    George G. Zhanel
    Christina Deng
    Sheryl Zelenitsky
    Courtney K. Lawrence
    Heather J. Adam
    Alyssa Golden
    Liam Berry
    Frank Schweizer
    Michael A. Zhanel
    Neal Irfan
    Denice Bay
    Philippe Lagacé-Wiens
    Andrew Walkty
    Lionel Mandell
    Joseph P. Lynch
    James A. Karlowsky
    Drugs, 2021, 81 : 233 - 256
  • [3] Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia
    Zhanel, George G.
    Deng, Christina
    Zelenitsky, Sheryl
    Lawrence, Courtney K.
    Adam, Heather J.
    Golden, Alyssa
    Berry, Liam
    Schweizer, Frank
    Zhanel, Michael A.
    Irfan, Neal
    Bay, Denice
    Lagace-Wiens, Philippe
    Walkty, Andrew
    Mandell, Lionel
    Lynch, Joseph P., III
    Karlowsky, James A.
    DRUGS, 2021, 81 (02) : 233 - 256
  • [4] Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia
    Lee, Young Ran
    Jacobs, Katy Louise
    DRUGS, 2019, 79 (17) : 1867 - 1876
  • [5] Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia
    Young Ran Lee
    Katy Louise Jacobs
    Drugs, 2019, 79 : 1867 - 1876
  • [6] Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
    Bhavnani, Sujata M.
    Zhang, Li
    Hammel, Jeffrey P.
    Rubino, Christopher M.
    Bader, Justin C.
    Sader, Helio S.
    Gelone, Steven P.
    Wicha, Wolfgang W.
    Ambrose, Paul G.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 : 35 - 41
  • [7] Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumonia
    Bian, Xingchen
    Li, Nanyang
    Li, Yi
    Zhu, Xu
    Yu, Jicheng
    Hu, Yingying
    Yang, Haijing
    Wei, Qiong
    Wu, Xiaojie
    Wang, Jingjing
    Cao, Guoying
    Wu, Jufang
    Wang, Yang
    Zhang, Jing
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [8] Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
    File, Thomas M., Jr.
    Goldberg, Lisa
    Das, Anita
    Sweeney, Carolyn
    Saviski, John
    Gelone, Steven P.
    Seltzer, Elyse
    Paukner, Susanne
    Wicha, Wolfgang W.
    Talbot, George H.
    Gasink, Leanne B.
    CLINICAL INFECTIOUS DISEASES, 2019, 69 (11) : 1856 - 1867
  • [9] Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2019, 61 (1581): : 145 - 148
  • [10] Lefamulin-A New Antibiotic for Community-Acquired Pneumonia
    Malani, Preeti N.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (17): : 1671 - 1672
12345